Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Our pharmaceutical business features NGENLA® (somatrogon-ghla), also referred to as Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. We have partnered with Pfizer Inc. (“Pfizer”) for further development and commercialization of Somatrogon (hGH-CTP).
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q1 2026 · $113.0MThe company’s own SEC segment disclosure.
- Service$72.2M64%
- Intellectual Property And Other$14.0M12%
- Transfer Of Intellectual Property And Other$14.0M12%
- Rayaldee$12.8M11%
OPKO Health, Inc. (OPK) reported revenue of $124M in Q1 2026 (quarter ended March 31, 2026), down 17% from the same quarter a year earlier. That came with a gross margin of 37% and net loss of $55M. For the full year FY2025, revenue was $607M (−15% year on year) and net income −$226M. Its largest product in 2026-Q1 was Service at $72M, 64% of the disclosed total, just ahead of Intellectual Property And Other at 12%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #15 of 29 by Smart Score